NICE recommends Lucentis (Novartis) for Diabetic Macular Oedema
NICE will now recommend Lucentis (ranibizumab) from Novartis for the treatment of Diabetic Macular Oedema. This is a change from previous draft guidance, which recommended against using the drug for this condition, The new decision is made after after Novartis agreed to drop the price of its drug.
In draft guidance, Lucentis is now recommended as an option for treating visual impairment caused by Diabetic Macular Oedema. A final decision is expected by February 2013. At present only laser photocoagulation is recommended for this condition.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.